中生製藥(01177.HK)抗骨質疏鬆藥通過內地仿製藥一致性評價
中國生物製藥(01177.HK)公布,集團的抗骨質疏鬆藥物「阿法骨化醇軟膠囊」(商品名:蓋諾真)已獲中國國家藥品監督管理局頒發藥品補充申請批准通知書,獲通過仿製藥質量和療效一致性評價,為國內同品種首家通過一致性評價。
集團指,阿法骨化醇是一種活性維生素D3類藥物,適用於治療腎性骨營養不良、術後性或特發性甲狀旁腺功能低下症、假性甲狀旁腺功能低下症等,是治療和預防骨質疏鬆的基礎用藥,該膠囊已入選國家基本藥物目錄。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.